Abstract
This review focuses on the activity of gemifloxacin, a new respiratory fluoroquinolone, against the two most important bacterial pathogens associated with lower respiratory tract infections, namely Streptococcus pneumoniae and Haemophilus influenzae.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Drug Resistance, Multiple
-
Fluoroquinolones / pharmacology*
-
Fluoroquinolones / therapeutic use
-
Gemifloxacin
-
Haemophilus Infections / drug therapy
-
Haemophilus Infections / microbiology
-
Haemophilus influenzae / drug effects*
-
Humans
-
Naphthyridines / pharmacology*
-
Naphthyridines / therapeutic use
-
Pneumococcal Infections / drug therapy
-
Pneumococcal Infections / microbiology
-
Streptococcus pneumoniae / drug effects*
Substances
-
Anti-Bacterial Agents
-
Fluoroquinolones
-
Naphthyridines
-
Gemifloxacin